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Abstract
Background: Cognitive-behavioral therapy (CBT) is generally known to be efficacious in the treatment of social
phobia when applied in RCTs, namely when the treatment manual is based on the Clark-Wells approach. However,
little is known about the efficacy of manualized treatments in routine clinical practice (Phase IV of psychotherapy
research). The present study (SOPHO-PRAX) is a continuation of a large multicenter randomized clinical trial
(SOPHO-NET) and analyzes the extent to which additional training practitioners in manualized procedures enhances
treatment effect.
Methods/design: Thirty-six private practitioners will be included in three treatment centers and randomly
designated to either training in manualized CBT or no specific training. The treatment effects of the therapies
conducted by both groups of therapists will be compared. A total of 162 patients (n=116 completers; n=58 per
condition) will be enrolled. Liebowitz Social Anxiety Scale (LSAS) will serve as primary outcome measure. Remission
from social phobia is defined as LSAS total ≤30 points. Data will be collected at treatment begin, after 8, 15, and 25
sessions (50 min each), at treatment completion, as well at 6 and 12 months post-treatment.
Discussion: The present CBT trial combines elements of randomized controlled trials and naturalistic studies in an
innovative way. It will directly inform about the incremental effects of procedures established in a controlled trial
into clinical practice. Study results are relevant to healthcare decisions and policy. They may serve to improve
quality of treatment, and shorten the time frame between the development and widespread dissemination of
effective methods, thereby reducing health cost expenditure.
The results of this study will not only inform about the degree to which the new methods lead to an improvement
of treatment course and outcome, but also about whether the effects of routine psychotherapeutic treatment are
comparable to those of the controlled, strictly manualized treatments of the SOPHO-NET study.
Trial registration: ClinicalTrials.gov identifier: NCT01388231. This study was funded by the German Federal Ministry
of Education and Research (SOPHO-NET: BMBF 01GV0607; SOPHO-PRAX: BMBF 01GV1001).
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Social phobia (SP), also known as social anxiety disorder
(SAD), represents a chronic and debilitating mental dis-
order characterized by persistent fears of one or more
social situations in which the person is exposed to un-
familiar persons and expects to be scrutinized by others.
The person affected fears acting (or showing anxiety
symptoms) in a way that will cause embarrassment and
humiliation [1]. DSM-IV-TR criteria indicate that,
though such fears are recognized as unreasonable and
excessive, exposure to such feared situations may invari-
ably trigger anxiety, which may escalate to a situation-
bound or predisposed panic attack. The fears in social
phobia can cause clinically significant distress or impair-
ment in social, occupational, or other important areas of
functioning [1]. Epidemiological studies have also shown
co-morbid psychopathology (other anxiety disorder,
mood disorders, substance abuse) to be common for this
disorder (for example [2]).
Prevalence rates have been found to vary across coun-
tries. A recent study by Ruscio et al. [3] found estimates
of lifetime and 12-month prevalence at 12.1% and 7.1%,
respectively. In Europe, a lifetime prevalence of 6.65%,
and a 12-month prevalence estimate of 2.0% were found
[4,5]. The age of onset tends to be located between prea-
dolescence and early adulthood, for example between 10
and 16.6 years [6]. Onset at an age later than 25 years
appears to occur less frequently [3,7].
Epidemiological studies have shown SP to be typically
chronic in its course (for example [8]). Full remission
from SP symptoms, though infrequent, tends to occur
within 8 years when no treatment is provided [9,10].
Probably due to the overlap in the symptoms of shyness
and SP (that is, heightened autonomic arousal in social
situations (for example increased heart rate, blushing,
sweating, [11], social skills deficits, such as low eye con-
tact)), avoidance of social interactions, and cognitions
reflecting fear of negative evaluation [12-14], those
affected by the latter may not be easily detected and thus
remain untreated [6].
Development and dissemination of efficacious treat-
ments for SP is therefore in clear demand. CBT for so-
cial phobia is generally efficacious (for example [15,16]).
RCT trials favoring the Clark-Wells approach [17] show
the highest effect sizes [18,19], even outperforming
standard pharmacological treatment [18] and suggesting
specifically this approach to be distributed to routine
clinical practice. However, to date a large disconnect be-
tween research and practice appears to hinder the devel-
opment of psychology, both as a science and as a
profession. Access to evidence-based psychological treat-
ments has become a growing problem in the last
10 years. In spite of the support by healthcare author-
ities, the urgently needed evidence and consensus
regarding the success of implementation of such treat-
ments, in addition to the measurement of successful
training outcomes, continues to be missing [20]. Specif-
ically for social phobia, the quality and effectiveness of
CBT in routine practice remains unknown.
To the best of the authors’ knowledge, there is also no
current research: (1) directly examining the effects of
additional training in a manualized and highly effective
procedure on outcome in routine CBT for social phobia;
and (2) testing the effectiveness of CBT for social phobia
(in the control group), usually delivered in the private
practices in Germany.
Hence, as a continuation of the Social Phobia Psycho-
therapy Research Network (SOPHO-NET, [21]), the
present study (SOPHO-PRAX) is designed as a multi-
center randomized clinical trial based on a standard
protocol and a set of standardized measures for the as-
sessment and treatment of SP. The present study proto-
col aims at testing the potential of the Clark and Wells
CBT approach to the treatment of SP evaluated in the
main trial of this research cooperation [21] in order to
improve the effects of routine psychotherapies. It there-
fore appears important to investigate in detail to what
extent such treatment methods can be transferred from
controlled trials to the less structured setting of routine
clinical care, and whether the healthcare system benefits
from such developments. The rationale of this study
thus represents Phase IV of psychotherapy research.
Methods/design
Study centers
The present study is being conducted by three trial sites,
namely the Universities of Dresden (Prof. Dr. Hoyer),
Frankfurt (Prof. Dr. Stangier), and Göttingen (Prof. Dr.
Leibing), each coordinating at least 12 private practices.
Participants
Patient inclusion and exclusion criteria are listed in
Table 1. The sample fulfilling these criteria are consid-
ered representative for social phobia patients qualifying
for treatment in an outpatient setting. Assuming a drop-
out rate of 25% over a period of 2 years, a total of 162
patients are planned to be enrolled in the study (that is
54 patients in each center; see sample size calculation).
Patients will only be able to enrol once in the present
trial. Participants will be able to directly contact the trial
centre in response to advertisements via the internet,
flyers, or newspaper articles. Alternatively, they will be
referred to by healthcare practitioners (that is, medical
doctors or private practitioners in psychotherapy). Once
the diagnostician confirms the patient’s eligibility for the
study, the patient will select and contact a therapist from
a list of candidates for treatment. Only private practi-
tioners officially listed in the German chambers of
Crawcour et al. Trials 2012, 13:70 Page 2 of 9
http://www.trialsjournal.com/content/13/1/70psychotherapists will be recruited. Informed consent
from both the therapist and the patient will be collected.
All therapists will have to be certified in CBT. Inclusion
criteria for therapists are broad (that is, any age and gen-
der, living in the area of the trial center) as a function of
the naturalistic aspects of the present trial. However,
practitioners having recent training (within the last
5 years) in the Clark and Wells treatment of SP [17] will
be excluded from the study. Measures of allegiance to
the treatment condition and professional experience will
be collected via self-report of the therapists as well as
via expert ratings of video-documented sessions.
Interventions
The experimental intervention comprises training in
outpatient CBT for private practitioners, following the
manual by Stangier, Clark, and Ehlers [22]. The manual
follows the model of Clark and Wells [17] and prescribes
interventions which are as follows: derivation an idiosyn-
cratic version of the Clark and Wells model in cooper-
ation with the patient; manipulation of self-focused
attention and safety behaviors; application of video and
audio feedback to modify distorted self-imagery; behav-
ioral experiments in and out of the therapy room; atten-
tion shifts and interrogation of the social environment;
identification and modification of anticipatory and post-
event processing; identification of the patient’s dysfunc-
tional assumptions and modification using cognitive re-
structuring. CBT treatment as usual will serve as the
control condition. According to psychotherapy manuals
(for example [23]), up to 25+5 sessions are scheduled.
See Figure 1 for trial flow. Practitioners will receive two
separate blocks of training based on Stangier et al.’s
manual [22], each block with a mean duration of 12 h.
Practitioners in both groups will also be offered regular
group supervision (with a mean duration of 2 h).
Assessment
The time points of assessment are displayed in Figure 2.
Independent and trained SCID interviewers giving pa-
tient assessments are blind to the treatment condition.
Assessments will be made at baseline, that is, prior to
treatment onset (T1), at session 8 (T2), 15 (T3), and 25
(usually post-treatment, T4), at post-treatment (when
treatment duration is longer than 25 sessions, T5). Every
session is planned to have a 50-min duration. Follow-up
Table 1 Inclusion and exclusion criteria
Inclusion criteria Diagnosis of SP (SCID-I)
Liebowitz Social Anxiety Scale >30 (>60 for
generalized subtype)
Age 18 to 70 years
SP must be primary diagnosis (most severe disorder
according to ADIS-IV)
SP patients with co-morbid disorders will be
included, provided that SP is the primary diagnosis,
thus ensuring a clinically representative sample as
well as analyses of subgroups (for example, type of
SP, patients with co-morbid depressive disorder)
Exclusion criteria Psychotic disorder
Prominent risk of self-harm
Acute substance-related disorders
Personality disorders except for avoidant
Obsessive-compulsive or dependent personality
disorder (SCID-II) organic mental disorder
Severe medical conditions
Concurrent psychotherapeutic or
psychopharmacological treatment, with the
following exception: specific psychopharmacological
treatments (that is, tranquilizer, hypnotics,
neuroleptics, phytopharmaceuticals, and beta-
blockers prescribed as anxiolytics) should be
terminated prior to therapy onset
Anti-depressive medication represents no exclusion
criterion as long it is reliably and stably consumed
Figure 1 Intervention scheme/trial flow.
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after treatment; assessments at weeks 8 and 15 are per-
formed to ensure intent-to-treat analyses. Primary end-
point: assessment after 25 sessions; secondary endpoint:
post-treatment. Should treatment end at T4, measures
for T5 will also be collected.
Objectives and hypotheses
As a study combining the scientific benefits of rando-
mized controlled trials (efficacy studies) and naturalistic
studies (effectiveness research), its main objective is the
analysis of the effects of additional training for private
practitioners. Hence, the following question is investi-
gated: does training in manualized treatment increase
the effectiveness of psychotherapy for social phobia in
natural settings?
We expect the effects of CBT on social phobia to be
enhanced by training experienced therapists and by
systematic transfer of innovative manualized treatments
into practice. Thus, the specific hypotheses are as fol-
lows: (1) treatment effects achieved by private practi-
tioners trained with the manualized procedures (Group
1) will be superior to those achieved by therapists who
continue their standard treatment (Group 2); and (2)
treatment duration (in terms of number of sessions be-
tween treatment onset and finalization) in Group 1 will
be shorter.
Outcomes
Endpoints and outcome measures were chosen in ac-
cordance with the main trial of the SOPHO-NET study
[21]. Outcome measures include internationally used
valid and highly relevant measures of SP. The primary
outcome measure will be the Liebowitz Social Anxiety
Scale (LSAS [24]). Remission from social phobia is
defined as LSAS total scores ≤30 points. Secondary
Figure 2 Time points of assessment. 1) LSAS self rating, 2) LSAS observer rating.
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standard scales for social anxiety (SPAI [25], SPK [26],
SPV [27], BSPS [28]), depression (BDI [29]), and a scale
for quality of life and social functioning (EQ-5D [30]). In
addition we will assess emotional regulation (ASQ [31]),
helping alliance (HAQ [32]), the subjective evaluation of
sessions (STEPP [33]), as well as the reaction to treat-
ment (RTQ [34,35]). During diagnostics, a rating on
symptoms severity using the Clinical Global Impression
scale (CGI [36]) is also given. The majority of these
measures will also be used in a related trial of manua-
lized short-term psychodynamic therapy allowing for
high comparability between both trials [37]. Further-
more, patient sociodemographic data and costs of SP
treatment are assessed using selected items of the Ger-
man adaptation of the client sociodemographic and ser-
vice receipt inventory (CSSRI; for example number of
treatment sessions, days of work disability [38]). All
instruments will be applied in both groups of this trial.
Using established cut-off scores for LSAS (≤30 points
[24]), the percentages of patients defined as remitted will
be assessed and statistically compared between the
group treated by specifically trained therapists and the
group receiving standard CBT.
Sample size calculation
The only study directly comparing performance of ther-
apy delivered under RCT conditions and routine care
refers to group CBT for social phobia [18] and showed a
small but significant advantage for the RCT therapies.
The difference between the Clark trials [17,18] and other
controlled trials suggests a much higher difference in the
to-be expected between-group effect sizes of our study
but only under the improbable assumption that trained
private practitioners will be comparably successful as the
specialized therapists in the Clark trials. Sholomskas
et al. [39], in a study directly testing the effects of add-
itional training, but not in the field of SP, reported an
average between group effect size of d=0.69 when com-
paring therapists who were trained in a seminar plus
supervision and therapists who used a manual without
further training with regard to their performance in
standardized role plays. However, this estimation does
not directly refer to the expected effect sizes for the
therapeutic benefit, which is the main outcome criterion
of this trial. Given this inconsistent information, we
choose to expect a more conservative effect size of
d=0.50 between Group 1 (trained therapists) and Group
2 (treatment-as-usual), for pragmatic reasons. We aimed
at estimating the sample size needed for a dichotomous
approach (remission rates according to the above
defined criterion, LSAS <30). In order to assure com-
parability with the parallel trial for psychodynamic
therapy [37] we introduced the same conservative
assumptions: (1) the ICC was set to 15% which is high
compared to similar studies [40]; and (2) for the primary
analysis (ITT) drop-outs will be analyzed as patients
with no remission. When assuming <50% remitters and
an equal drop-out rate in both conditions, the absolute
difference between remission rates will remain un-
changed, but the relative difference will be much greater
and will substantially enlarge the difference between
treatments.
In contrast to Wiltink et al.’s study protocol [37], the
average number of patients in a cluster was assumed to
be five, as we choose to collaborate more continuously
with the included therapists. Please note that this is the
only assumption differing from those made in [37]
resulting in a higher a priori sample size than in [37].
In order to detect a difference between Groups 1 and
2a tα=0.05 (one-tailed; see Discussion) with a power of
0.80, n=58 patients per group are required according to
the formula of Campbell et al. [40,41] for cluster-
randomization, given that five patients per therapist will
be treated (for a more comprehensive account, see [42]):
N ¼ 2  
σðzα þ zβÞ
E
 2
  1 þð m−1Þρ ½ 
¼ 2  
ðzα þ zβÞ
ES
 2
  1 þð m−1Þρ ½ 
(zα, z-value for probability of error type I alpha; zβ,z -
value for probability of error type II beta; σ, standard de-
viation of outcome; E, expected ES of outcome; m, mean
observations for each cluster; ρ, Intracluster correlation
coefficient (ICC); ES=E/σ, standardized effect size)
Given a conservative drop-out rate estimate of 25%
(taking into account slightly elevated drop-outs in a
practice study), a total of n=162 patients are required to
be allocated to the trial. Thus, n=54 patients will have
to be included in each center. According to data of the
Stangier et al. [43] study on social phobia, in which
patients were recruited in a comparable setting of Ger-
man psychotherapeutic care, 61% of 250 patients meet-
ing the inclusion criteria can expected to be finally
included. We estimate that not more than about 250
patients will have to be assessed for eligibility.
Randomization
Therapists will be randomly assigned either to a training
group (manualized CBT), in which they will undergo an
intensive training of the treatment manual for social
phobia, or to a control group (routine care), in which
the non-manualized CBT standard treatment is applied.
Private practitioners will be block randomized. Practi-
tioner randomization will be stratified for each trial cen-
ter using the nQuerie Advisor
W 6.01 software program
[44]. As participants in a naturalistic study, patients are
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not the therapist they have freely chosen has been
trained in manualized CBT. Diagnostic procedures are
performed by independent, blinded, and specially trained
assessors for diagnosis and observer-rated outcome mea-
sures. All diagnosticians are trained by one of the co-
authors (US), who was responsible for quality assurance
of CBT in the SOPHO-NET study and has extensive ex-
perience in conducting RCT of SP [43,45]. There will be
multimethod assessment of specific and non-specific
therapy outcome including both patient and assessor
perspective; control for drop-outs, intent-to-treat ana-
lyses. Generalizability of results will be established by
above defined inclusion and exclusion criteria (Table 1)
and by the multicenter approach.
Statistical analysis
Primary analyses
The following hypothesis will be tested: H0: μ manua-
lized≤μ standard vs. H1: μ manualized>μ standard-
where μ manualized and μ standard are the true
remission probabilities in the manualized treatment
group and the standard routine care group after the
treatment period, respectively.
Remission rates will be compared between specifically
trained and standard CBT group via logistic regression
using covariates for treatment, sex of the therapist, and
experience of the practitioner (as in [37]). For repeated
measures, as suggested by Wood et al. [46], random
effects models will be fitted of outcomes taking into ac-
count potential drop-outs (for further reference, see [42]
and [47]). Hypothesis 1 of this trial will be tested by the
group*time interaction (with dummy variables coding
the time effects at time points T4 to T7 as compared to
baseline measurement).
Further analyses will include: comparison of remission
rates across treatment groups at time points T4 to T7
using the chi-squared test of independence; cross-
sectional analyses at T4 to T7 comparing both patients
and therapists in the three study centers; analyses of co-
variance of outcomes at T4 to T7 considering patient
variables, taking into account potential differences be-
tween patients recruited by trained vs. those recruited by
non-trained therapists; and multiple regression analyses
to test whether diverse covariates including process vari-
ables predict different treatment outcomes. Regression
analysis will be applied to each treatment group separ-
ately. Should the results be similar, the sample will be
pooled.
A descriptive analysis will be made on drop-outs and
their covariates. Imputation methods will be considered
if necessary following an assessment of the missing value
structure [46].
Secondary analyses
Random effects analysis of treatment outcomes as a
function of time will also be employed to analyze asso-
ciations with questionnaire data and observer ratings
(SPAI, SPK, SPV, BSPS, BDI, EQ-5D, ASQ, HAQ,
STEPP, reaction to treatment, CGI). Moreover, analyses
to be performed will include the following: cross-
sectional analyses as above; analyses of subjects’ and
therapists’ conditions regarded as subgroup; SP treat-
ment costs (CSSRI) [38] will also be considered as
‘process variables’; again, a one-sided level of significance
at α=0.05 will be chosen (see Discussion).
Safety aspects
Trial progress, monitor data management, and patient
safety will be reviewed by the control center for clinical
studies (KKS), the Ethics Committee (EC) of the Tech-
nische Universitaet Dresden (Germany), and the Data
Monitoring and Safety Committee (DMSC).
Medical complications
Only psychological conditions according to the Inter-
national Classification of Diseases F00-F99 (‘Mental
and Behavioral Disorders’)w i l lb er e c o r d e da n dc l a s s i -
fied as adverse events. Any deterioration that results in
discontinuation of therapy (including suicidal risk and
hospitalization) will be notified immediately by the pri-
vate practitioner. Changes in psychological disorders
will also be notified by the therapist and assessed by
the diagnostician after session 25 of treatment, as well
as 6 and 12 months post-treatment.
Ethical issues
The trial has been approved by the responsible Ethics
Committee of the Technische Universitaet Dresden (EK:
183062010) and the Data Safety Monitoring Committee
(DSMC). Prior to assessment, patients will be informed
about design and procedures, and will be required to give
informed consent and may withdraw at any point without
any disadvantage. Participating patients will be provided
with a treatment consistent with good clinical practice
according to the EMEA guidelines (http://www.emea.eu.
int/pdfs/human/ewp/363503en.pdf) for the diagnosis and
treatment of SP. Suicidal tendencies will be examined
regularly by the private practitioner. Should the need arise,
outpatient services will be available and admission to co-
operating clinics will also be possible. For further care,
patients that cannot be included in the study will either be
added to the practitioner’s general waitlist for further diag-
nosis and treatment or receive information on alternative
potential healthcare practitioners upon request.
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In the last decade, several authors have emphasized the
large gap between therapeutic treatments validated at uni-
versity institutions and the treatments applied in ‘everyday
practice’ (for example [20,48,49]). These researchers argue
for an increasingly efficient and effective dissemination of
evidence-based treatments in light of empirical data indi-
cating that, while such psychological treatments are being
developed for a variety of psychopathological conditions
(for an overview for depression see [50], for anxiety [51]),
their application into routine clinical practice remains
impaired. The factors to which the cause of this problem
has been attributed to include a lack of knowledge about
the effective transmission of CBT skills, the mechanism of
action of CBT, and the minimum dose that patients re-
quire, in addition to the difficulties in measuring quality of
therapy [52].
As a means to bridge this gap, the present study
(SOPHO-PRAX) represents a first attempt to test the
transferability of new CBT treatment options to the pri-
vate clinical practice under controlled conditions.
SOPHO-PRAX thus implies a continuation of the multi-
center project evaluating the efficacy of cognitive behav-
ioral therapy (CBT) and psychodynamic short-term
therapy (STPP) (SOPHO-NET [21]). The novelty of the
present CBT trial lies in the advantage of combining the
elements of randomized controlled trials and naturalistic
studies. It will directly inform about the incremental
effects of procedures established in a controlled clinical
trial into practice. Study results may be of great rele-
vance to healthcare policy, health insurance companies,
and the statutory boards of psychotherapists. They may
serve to improve quality of treatment and shorten the
timeframe between the development and widespread use
of effective methods, thereby reducing health cost of
expenditures [53]. The design of SOPHO-PRAX thus
aims to further a faster and more widespread dissemin-
ation of effective treatments. As one study center is
located in East Germany, study results will be of specific
importance for deliverance of evidence-based psycho-
therapeutic interventions in this region and its unmet
needs for psychotherapy.
The present study will also be the first to include sys-
tematic CBT training of private practitioners in the field
of psychotherapy in the German healthcare system. It
will help clarify whether clinical practitioners will gener-
ally regard the new CBT approaches as helpful for their
work, and ascertain to what degree they will integrate
the new methods into their clinical routine. As we spe-
cifically expected the new methods to be superior, it
needs to be mentioned that we choose one-sided testing
and an alpha of 0.05 as appropriate for a superiority trial
[54]. There are two reasons for this decision. Firstly, in
the field under investigation there is clear and robust
evidence (not just expectation) that the manualized ap-
proach of CBT for social phobia according to Clark and
Wells is the most efficacious among other CBT treat-
ments (see [15]). It follows that the scientific hypothesis
to be tested is one-sided. Secondly, as our study ap-
proach is that of a transfer or dissemination trial of an
already established manualized procedure, only a clear
advantage of this procedure over the reference interven-
tion (non-manualized treatment) would have conse-
quences for practice. Given these two conditions (that is,
one-sidedness of scientific hypothesis and practice rele-
vancy for superiority of the to-be implemented treat-
ment only), we followed the recommendation of
authors, such as Bland and Altmann [55] or Knottnerus
and Bouter [56], and calculated the a priori sample size
estimation based on one-sided testing. This approach
warrants that the sample size is not larger than needed
and the study is economic.
However, the clear methodological disadvantage of this
decision has to be emphasized: Although it is not our
scientific hypothesis, we can certainly not rule out
‘harm’, which in our case would mean superiority of the
(non-manualized) reference treatment over the to-be
implemented manualized one. Given the logic of the
one-sided analysis, no statistical testing whether the
standard procedure is superior to the manualized one
can be made. Accordingly, a negative result in a super-
iority trial (like ours) would not prove that the investi-
gated therapies are equivalent [54].
Nevertheless, the results of this study will not only in-
form about the degree to which the new methods lead to
an improvement of treatment course and outcome, but
also about whether the effects of routine psychothera-
peutic treatment are comparable to those of the con-
trolled, strictly manualized treatments of the SOPHO-
NET study [21]. Finally, this study will allow an estimate
of the reduction in treatment duration and costs made
possible through implementation of treatment manuals
into clinical practice. All these questions will be examined
in a methodologically rigorous manner, as they seem
highly relevant both for the domain of social phobia and
the dissemination of psychosocial treatments in general.
Trial status
Patient recruitment for the present trial is ongoing and
expected to be completed by September 2013. Therapies
are expected to be completed in 2014.
Abbreviations
ANOVA: Analysis of variance; ASQ: Affective Style Questionnaire; ADIS-
IV: Diagnostic interview; AE: Adverse event; BDI: Beck Depression Inventory;
BMBF: Federal Ministry of Education and Research; BSPS: Brief Social Phobia
Scale; CBT: Cognitive behavioral therapy; CRF: Case report form; CGI: Clinical
Global Impression scale; CSSRI: Client Sociodemographic and Service Receipt
Inventory; DMSC: Data Monitoring and Safety Committee; DSM-IV-
TR: Diagnostic and Statistical Manual of Mental Disorders 4th edition, text
Crawcour et al. Trials 2012, 13:70 Page 7 of 9
http://www.trialsjournal.com/content/13/1/70revision; EC: Ethics Committee; EQ-5D: Quality of life questionnaire; ES: Effect
size; HAQ: Helping Alliance Questionnaire; ICC: Intracluster correlation
coefficient; ICD-10: International Classification of Diseases; ITT: Intention to
treat; KKS: Control center for clinical studies; LOCF: Last observation carried
forward; LSAS: Liebowitz Social Anxiety Scale; RCT: Randomized clinical trial;
SAD: Social Anxiety Disorder; RTQ: Reaction to treatment questionnaire;
SAD: Social anxiety disorder; SAE: Serious Adverse Event; SCID: Structured
Clinical Interview for DSM Disorders; SOPHO-NET: Social Phobia
Psychotherapy Research Network; SOPHO-PRAX: Study on the transfer of
manualized CBT for social phobia into clinical practice; SP: Social Phobia;
SPAI: Social Phobia and Anxiety Inventory; SPK: Social Cognitions
Questionnaire; STPP: Short-Term Psychodynamic Psychotherapy; SPV: Social
Behavior Questionnaire; STEPP: Session evaluation sheet; T1-T7: Time points
of assessment.
Competing interests
The authors declare that they have no competing interests. JH received
speaking honoraries from Astra-Zeneca for a project unrelated to the present
trial.
Authors’ contributions
SC and JH completed the first draft of the manuscript. JW, EL, and US added
significant content to the first draft and contributed to its critical revision. JH,
EL, US, SC, and JW substantially contributed to the conception and the
design of the study. All authors read and approved the final manuscript.
Acknowledgement and funding
The study is funded by the German Ministry of Education and Research
(BMBF) (01 GV 1001).
Author details
1Clinical Psychology and Psychotherapy, Technische Universität/University of
Technology Dresden, Institutsambulanz und Tagesklinik IAP-TUD GmbH,
Hohe Straße 53, 01187, Dresden, Germany.
2Abteilung Psychosomatische
Medizin und Psychotherapie Zentrum Psychosoziale Medizin, Georg-August
University, von-Siebold-Str, 5, 37075, Göttingen, Germany.
3Institut für
Psychologie - Klinische Psychologie und Psychotherapie, Goethe University
Frankfurt, Varrentrappstr. 40-42, 60486, Frankfurt am Main, Germany.
4Clinic of
Psychosomatic Medicine and Psychotherapy, University Medical Center of
the Johannes Gutenberg University of Mainz, Untere Zahlbacher Straße 8,
55131, Mainz, Germany.
Received: 26 January 2012 Accepted: 25 April 2012
Published: 30 May 2012
References
1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders DSM-IV-TR Fourth Edition (Text Revision). Washington: APA; 2000.
2. Fehm L, Beesdo K, Jacobi F, Fiedler A: Social anxiety disorder above and
below the diagnostic threshold: prevalence, comorbidity and
impairment in the general population. Soc Psychiatry Psychiatr Epidemiol
2008, 43:257–265.
3. Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC: Social fears
and social phobia in the United States: results from the National
Comorbidity Survey Replication. Psychol Med 2008, 38:15–28.
4. Fehm L, Pelissolo A, Furmark T, Wittchen H-U: Size and burden of social
phobia in Europe. Eur Neuropsychopharmacol 2005, 15:453–462.
5. Wittchen HU, Jacobi F: Die Versorgungssituation psychischer Störungen
in Deutschland. Eine klinisch-epidemiologische Abschätzung anhand des
Bundes-Gesundheitssurveys 1998. Bundesgesundheitsbl Gesundheitsforsch
Gesundheitsschutz 2001, 44:993–1000.
6. Wittchen HU, Fehm L: Epidemiology and natural course of social fears
and social phobia. Acta Psychiatr Scand 2003, 108:(Suppl 1)4–18.
7. Beesdo K, Bittner A, Pine DS, Stein MB, Höfler M, Lieb R, Wittchen H-U:
Incidence of social anxiety disorder and the consistent risk for secondary
depression in the first three decades of life. Arch Gen Psychiatry 2007,
64:903–912.
8. DeWit DJ, Ogborne A, Offord DR, McDonald K: Antecedents of the risk of
recovery from DSM-III social phobia. Psychol Med 1999, 29:569–582.
9. Keller MB: The lifelong course of social anxiety disorder: a clinical
perspective. Acta Psychiatr Scand 2003, 108(Suppl 1):85–94.
10. Yonkers KA, Dyck IR, Keller MB: An eight-year longitudinal comparison of
clinical course and characteristics of social phobia among men and
women. Psychiatr Serv 2001, 52:637–643.
11. Beidel DC, Turner SM, Dancu CV: Physiological, cognitive, and behavioral
aspects of social anxiety. Behav Res Ther 1985, 23:109–117.
12. Heimberg RG, Hope DA, Dodge CS, Becker RE: DSM-III-R subtypes of social
phobia: comparison of generalized social phobics and public speaking
phobics. J Nerv Ment Dis 1990, 178:172–179.
13. Herbert JD, Hope DA, Bellack AS: Validity of the distinction between
generalized social phobia and avoidant personality disorder. J Abnorm
Psychol 1992, 101:332–339.
14. Ludwig R, Lazarus P: Relationship between shyness in children and
constricted cognitive control as measured by the Stroop Color-Word
Test. J Consult Clin Psych 1983, 51:386–389.
15. Powers MB, Sigmarsson SR, Emmelkamp PMP: A meta-analytic review of
psychological treatments for social anxiety disorder. Int J Cogn Ther 2008,
1:94–113.
16. Acarturk C, Cujpers P, van Straten A, de Graaf R: Psychological treatment
of social anxiety disorder: a meta-analysis. Psychol Med 2009, 39:241–
254.
17. Clark D, Wells A: A cognitive model of social phobia.I nIn Social phobia:
Diagnosis, assessment, and treatment. Edited by Heimberg R, Liebowitz M,
Hope D, Schneier F. New York: Guilford; 1995:69–93.
18. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H,
Flower T, Davenport C, Louis B: Cognitive therapy versus Fluoxetine in
generalized social phobia: a randomized placebo-controlled trial. J
Consult Clin Psych 2003, 71:1058–1067.
19. Clark DM, Ehlers A, Hackman A, McManus F, Fennell M: Cognitive therapy
versus exposure and applied relaxation in Social Phobia: a randomized
controlled trial. J Consult Clin Psych 2006, 74:568–578.
20. Barlow DH: The dissemination and implementation of evidence-based
psychological treatments – a review of current efforts. Am Psychol 2004,
59:869–878.
21. Leichsenring F, Hoyer J, Beutel M, Herpertz S, Hiller W, Irle E, Joraschky P,
König HH, de Liz TM, Nolting B, Pöhlmann K, Salzer S, Schauenburg H,
Stangier U, Strauss B, Subic-Wrana C, Vormfelde S, Weniger G, Willutzki U,
Wiltink J, Leibing E: The Social Phobia Psychotherapy Research Network.
The first multicenter randomized controlled trial of psychotherapy for
social phobia: rationale, methods and patient characteristics. Psychother
Psychosomat 2009, 78:35–41.
22. Stangier U: Clark DM, Ehlers A: Soziale Phobie. Göttingen: Hogrefe; 2006.
23. Stangier U, Ehlers A: Clark DM: Soziale Phobie. Fortschritte der
Psychotherapie. Göttingen: Hogrefe; 2006.
24. Stangier U, Heidenreich T, Stangier U, Heidenreich T: Liebowitz Soziale
Angst Skala.I nInternationale Skalen für Psychiatrie. 5th edition. Edited by
Collegium Internationale Psychiatrie Scalarum (CIPS).; 2005.
25. Fydrich T: Soziale Phobie und Angstinventar (SPAI). Deutschsprachige
Adaptation des "Social Phobia and Anxiety Inventory" von Turner und Beidel.
Göttingen: Hogrefe; 2003.
26. Stangier U, Heidenreich T, Peitz M: Soziale Phobien. Ein kognitiv-
verhaltenstherapeutisches Behandlungsmanual. Weinheim: Beltz; 2003.
27. Stangier U, Heidenreich T, Schermelleh-Engel K: Safety behaviors and
social performance in patients with generalized social phobia. J
CogPsychother 2006, 20:417–431.
28. Davidson JR, Potts NL, Richichi EA, Ford SM, Krishnan KR, Smith RD, Wilson
W: The brief social phobia scale. J Clin Psychiat 1991, 52(Suppl 1):48–51.
29. Hautzinger M, Bailer M, Worall H: Keller, F: Das Beck Depressionsinventar. Bern:
Huber; 1995.
30. von der Schulenburg JM Graf, Claes C, Greiner W, Uber A: Die deutsche
Version des EuroQol-Fragebogens. Zeitschrift für Gesundheitswissenschaften
1998, 6:3–20.
31. Hoffmann SG, Kashdan B: The affective style questionnaire:
development and psychometric properties. J Psychopathol Behav 2009,
32:255–263.
32. Bassler M, Potratz B, Krauthauser H: Der "Helping Alliance Questionaire"
(HAQ) von Luborsky. Möglichkeiten zur Evaluation des therapeutischen
Prozesses von stationärer Psychotherapie. Psychotherapeut 1995, 40:23–32.
33. Krampen G: Stundenbogen für die Allgemeine und Differentielle
Einzelpsychotherapie. Göttingen: Hogrefe; 2002.
Crawcour et al. Trials 2012, 13:70 Page 8 of 9
http://www.trialsjournal.com/content/13/1/7034. Borkovec TD, Nau SD: Credibility of analogue therapy rationales. J Behav
Ther Exp Psy 1972, 3:257–260.
35. Holt CS, Heimberg RG: The reaction to treatment questionnaire:
measuring treatment credibility and outcome expectancies. The Behavior
Therapist 1990, 13:213–214.
36. Zaider TI, Heimberg RG, Fresco DM, Schneier FR, Liebowitz MR: Evaluation
of the clinical global impression scale among individuals with social
anxiety disorder. Psychol Med 2003, 33:611–622.
3 7 . W i l t i n kJ ,R u c k e sC ,H a s e l b a c h e rA ,C a n t e r i n oM ,L e i c h s e n r i n gF ,J o r a s c h k yP ,
Leweke F, Pöhlmann K, Beutel ME: Transfer of manualized Short Term
Psychodynamic Psychotherapy (STPP) for social phobia into clinical practice:
study protocol for a cluster-randomised controlled trial. Trials 2011, 12:142.
38. Roick C, Kilian R, Matschinger H, Bernert S, Mory C, Angermeyer MC:
German adaptation of the client sociodemographic and service receipt
inventory - an instrument for the cost of mental health care. Psychiatr
Prax 2001, 28(Suppl 2):84–90.
39. Sholomskas DE, Syracuse-Siewert G, Rounsaville BJ, Ball SA, Nuro KF, Carroll
KM: We don’t train in vain: A dissemination trial of three strategies of
training clinicians in cognitive-behavioral therapy. J Consult Clin Psych
2005, 73:106–115.
40. Campbell MJ, Mollison J, Grimshaw JM: Cluster trials in implementation
research: estimation of intracluster correlation coefficients and sample
size. Stat Med 2001, 20:391–399.
41. Campbell MJ, Elbourne DR, Altman DG: CONSORT statement: extension to
cluster randomised trials. BMJ 2004, 238:702–708.
42. Donner A, Klar N: Design and Analysis of Cluster Randomization Trials in
Health Research. London: Arnold; 2000.
43. Stangier US, Heidenreich T, Peitz M, Lauterbach W, Clark DM: Cognitive
therapy for social phobia: individual versus group treatment. Behav Res
Ther 2003, 41:991–1007.
44. Elashoff JD: nQuery Advisor. Version 6.01 User’s Guide. Los Angeles, CA:; 2005.
45. Stangier US, Schramm E, Heidenreich T, Berger M, Clark DM: Cognitive
therapy vs interpersonal psychotherapy in social anxiety disorder - a
randomized controlled trial. Arch Gen Psychiatry 2011, 68:692–700.
46. Wood AM, White IR, Hillson M, Carpenter J: Comparison of imputation and
modelling methods in the analysis of a physical activity trial with
missing outcomes. Int J Epidemiol 2005, 34:89–99.
47. Campbell MK, Mollison J, Steen N, Grimshaw JM, Eccles M: Analysis of
cluster randomized trials in primary care: a practical approach. Fam Pract
2000, 17:192–196.
48. Gaston JE, Abbott MJ, Rapee RM, Neary SA: Do empirically supported
treatments generalize to private practice? A benchmark study of a
cognitive-behavioural group treatment programme for social phobia. Br
J Clin Psychol 2006, 45:33–48.
49. Dimeff LA, Koerner K, Woodcock EA, Beadnell B, Brown MZ, Skutch JM, Paves
AP, Bazinet A, Harned MS: Which training method works best? A
randomized controlled trial comparing three methods of training clinicians
in dialectical behavior therapy skills. Behav Res Ther 2009, 47:921–930.
50. Thoma NC, McKay D, Gerber AJ, Milrod BL, Edwards AR, Kocsis JH: A
quality-based review of randomized controlled trials of cognitive-
behavioral therapy for depression: an assessment and metaregression.
Am J Psychiatry 2012, 169:22–30.
51. Ost LG: Cognitive behavior therapy for anxiety disorders: 40 years of
progress. Nord J Psychiatry 2008, 62(Suppl 1):5–10.
52. Shafran R, Clark DM, Fairburn CG, Arntz A, Barlow DH, Ehlers A, Freeston M,
Garety PA, Hollon SD, Ost LG, Salkovskis PM, Williams JMG, Wilson GT: Mind
the gap: Improving the dissemination of CBT. BRAT 2009, 47:902–909.
53. Beutel ME, Rasting M, Stuhr U, Rüger B, Leuzinger-Bohleber M: Assessing
the impact of psychoanalyses and long-term psychoanalytic therapies
on health care utilization and costs. Psychother Res 2004, 14:146–160.
54. Christensen E: Methodology of superiority vs. equivalence trials and non-
inferiority trials. J Hepatol 2007, 46:947–954.
55. Bland JM, Altman DG: One and two sided tests of significance. BMJ 1994,
309:248.
56. Knottnerus JA, Bouter LM: The ethics of sample size: Two-sided testing
and one-sided thinking. J ClinEpidemiol 2001, 54:109–111.
doi:10.1186/1745-6215-13-70
Cite this article as: Crawcour et al.: Transfer of manualized CBT for social
phobia into clinical practice (SOPHO-PRAX): a study protocol for a
cluster-randomized controlled trial. Trials 2012 13:70.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Crawcour et al. Trials 2012, 13:70 Page 9 of 9
http://www.trialsjournal.com/content/13/1/70